JP6522790B2 - Oct4が導入されたヒト体細胞からダイレクトリプログラミングを用いた希突起膠前駆細胞を誘導する方法 - Google Patents
Oct4が導入されたヒト体細胞からダイレクトリプログラミングを用いた希突起膠前駆細胞を誘導する方法 Download PDFInfo
- Publication number
- JP6522790B2 JP6522790B2 JP2017560793A JP2017560793A JP6522790B2 JP 6522790 B2 JP6522790 B2 JP 6522790B2 JP 2017560793 A JP2017560793 A JP 2017560793A JP 2017560793 A JP2017560793 A JP 2017560793A JP 6522790 B2 JP6522790 B2 JP 6522790B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- inhibitor
- agonist
- tgf
- forskolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/065—Modulators of histone acetylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
- C12N2506/092—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells from hair cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Developmental Biology & Embryology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Description
以下、実施例を通じて本発明をより詳しく説明する。これらの実施例は、単に本発明をより具体的に説明するためのものであって、本発明の要旨によって本発明の範囲がこれらの実施例に限定されないことは、当業界における通常の知識を有する者にとって自明である。
1−1:Sox10レポーターシステムを利用した低分子性物質の選別
本発明者らは、遺伝子の導入なしに低分子性物質だけでマウス細胞から神経幹細胞を誘導できる条件を確立したことがある(KR10−1357402)。したがって、以前の研究で確立された低分子性物質に基づいてヒト体細胞を希突起膠前駆細胞に誘導し得る新しい条件を確立するために、希突起膠細胞の発達に重要であると知られている遺伝子であるSox10レポーターシステム(Sox10::eGFP)を利用して低分子性物質を選別した(図1)。
ATVP:0.5μMのA83−01+0.5μMのチアゾビビン+0.1mMのバルプロ酸(VPA)+0.5μMのパルモルファミン、RG108:0.5μMのRG108、BIX01294:0.25μMのBIX01294、SP600125:2μMのSP600125、LPA:2μMのリゾホスファチジン酸(Lysophosphatidic acid)、Bayk:2μMのBayk8644、Fsk:10μMのホルスコリン(Forskolin)、Dex:1μMのデキサメタソン(Dexamethasone)、EX527:5μMのEX527、Rolipram:2μMのロリプラム(Rolipram)
実施例1−1のReprogramming Media(RM)に含有されたKnockout Serum Replacement(KSR)の場合、Oct4の過発現と共に利用される場合、神経幹細胞への転換が可能であるという報告がある。
実施例1−1のレポーター細胞株として使用されたSox10::eGFP線維芽細胞(fibroblasts)の場合、胚芽幹細胞(ES cell)から分化を通じて得られた細胞であるので、線維芽細胞でない他の幹細胞を完全に排除できないため、体細胞からのダイレクトリプログラミングであると見られない。また、米国のShengding研究チームとMickie Bhatia研究チームがヒト体細胞にOct4を過発現させた後、神経幹細胞を確立する過程で、KSR(Knock out Serum Replacement)が入った培養液を使用したため、本実施例では、胚芽(Embryo)由来でないヒト体細胞から希突起膠前駆細胞の上位幹細胞である神経幹細胞を経由せずにダイレクトリプログラミングを誘導するために、KSRが入ったRM(Reprogramming Media)を使用しなかった(図7)。
3−1:希突起膠細胞への分化
実施例2で誘導された希突起膠前駆細胞の希突起膠細胞への分化能力を確認するために、従来の培養液において成長因子を除去し、分化培養液(DMEM High glucose+1XN2+1XB27(without vitamin A)+1%ペニシリン/ストレプトマイシン+1%非必須アミノ酸+50μg/mlのアスコルビン酸+40ng/mlのT3(triiodo−l−thyronine)+0.5μMのチアゾビビン+10μMのホルスコリン+10ng/mlのHuman Leukemia Inhibitor Factor(LIF))に変えた。
希突起膠前駆細胞の生体内分化能および細胞治療剤としての治療能を検証するために、多発性硬化症動物モデル(Experimental Autoimmune Encephalomyelitis mouse model、EAE mouse model)に実施例2で誘導された希突起膠前駆細胞を移植した。
本実施例では、iOPCを確立する過程で、iOPCがOct4過発現後に誘導された神経幹細胞から分化したものでなく、ダイレクトリプログラミングを用いて確立されたことを検証するために、誘導7日間の遺伝子発現の変化をリアルタイムPCRを通じて確認した。
希突起膠前駆細胞への誘導が包皮線維芽細胞(Foreskin fibroblast)だけでなく、他のヒト体細胞でも可能であるかを確認するために、それぞれ異なる5種の細胞(毛嚢毛乳頭細胞(Hair−follicle dermal papilla)、羊膜幹細胞(Amniotic derived Stem Cells)、IMR90肺線維芽細胞、皮膚線維芽細胞(Dermal Fibroblasts)および脂肪幹細胞(Adipose−derived Stem Cells))にOct4を過発現させた後、希突起膠前駆細胞に誘導した。
Claims (17)
- Oct4蛋白質をコードする核酸分子が導入されたヒト体細胞を(i)TGF−βタイプI受容体阻害剤(TGF−βtype I receptor inhibitor);(ii)ROCK阻害剤(Inhibitor of Rho−associated kinase);(iii)ヒストン脱アセチル化酵素阻害剤(Histone deacetylase inhibitor);および(iv)Shh作動剤(Sonic hedgehog agonist)を含有する培地で培養する段階を含み、TGF−βタイプI受容体阻害剤はA83−01であり、ROCK阻害剤はチアゾビビン(Thiazovivin)であり、ヒストン脱アセチル化酵素阻害剤はバルプロ酸(Valproic Acid)であり、Shh作動剤はパルモルファミン(Purmorphamine)である、ダイレクトリプログラミング(direct reprogramming)を用いてヒト体細胞から希突起膠前駆細胞を誘導する方法。
- 前記培地は、カルシウムチャネル作動剤(Calcium channel agonist)をさらに含有することを特徴とする、請求項1に記載の方法。
- ヒト体細胞を(i)TGF−βタイプI受容体阻害剤(TGF−βtype I receptor inhibitor);(ii)ROCK阻害剤(Inhibitor of Rho−associated kinase);(iii)ヒストン脱アセチル化酵素阻害剤(Histone deacetylase inhibitor);および(iv)Shh作動剤(Sonic hedgehog agonist)を含有する培地で培養する段階を含み、前記ヒト体細胞は、培養前に、培養と同時に、または培養後にOct4蛋白質で処理され、TGF−βタイプI受容体阻害剤はA83−01であり、ROCK阻害剤はチアゾビビン(Thiazovivin)であり、ヒストン脱アセチル化酵素阻害剤はバルプロ酸(Valproic Acid)であり、Shh作動剤はパルモルファミン(Purmorphamine)である、ダイレクトリプログラミング(direct reprogramming)を用いてヒト体細胞から希突起膠前駆細胞を誘導する方法。
- 前記培地は、カルシウムチャネル作動剤(Calcium channel agonist)をさらに含有することを特徴とする、請求項3に記載の方法。
- 前記培地は、RG108、BIX01294、SP600125、リゾホスファチジン酸(Lysophosphatidic acid)、Bayk8644、ホルスコリン(Forskolin)、デキサメタソン(Dexamethasone)、EX527およびロリプラム(Rolipram)よりなる群から選択されたいずれか一つをさらに含有することを特徴とする、請求項1に記載の方法。
- カルシウムチャネル作動剤は、ホルスコリン(Forskolin)であることを特徴とする、請求項2に記載の方法。
- 前記培地は、N2、B27、ペニシリン/ストレプトマイシン、非必須アミノ酸、bFGF、PDGFおよびアスコルビン酸が含まれたDMEMであることを特徴とする、請求項1に記載の方法。
- 前記ヒト体細胞は、包皮線維芽細胞(Foreskin fibroblast)、毛嚢毛乳頭細胞(Hair−follicle dermal papilla)、IMR90肺線維芽細胞および皮膚線維芽細胞(Dermal Fibroblasts)よりなる群から選択されることを特徴とする、請求項1に記載の方法。
- 前記希突起膠前駆細胞は、PDGFRa、A2B5、Olig2、Sox10、S100bおよびZFP536よりなる群から選択されるいずれか一つ以上のマーカーを発現することを特徴とする、請求項1に記載の方法。
- 前記希突起膠前駆細胞は、Sox1、Sox2およびPax6マーカーを発現しないことを特徴とする、請求項1に記載の方法。
- (i)TGF−βタイプI受容体阻害剤(TGF−βtype I receptor inhibitor);(ii)ROCK阻害剤(Inhibitor of Rho−associated kinase);(iii)ヒストン脱アセチル化酵素阻害剤(Histone deacetylase inhibitor);および(iv)Shh作動剤(Sonic hedgehog agonist)を有効成分として含み、TGF−βタイプI受容体阻害剤はA83−01であり、ROCK阻害剤はチアゾビビン(Thiazovivin)であり、ヒストン脱アセチル化酵素阻害剤はバルプロ酸(Valproic Acid)であり、Shh作動剤はパルモルファミン(Purmorphamine)である、Oct4蛋白質をコードする核酸分子が導入されたヒト体細胞またはOct4蛋白質で処理されたヒト体細胞からダイレクトリプログラミング(direct reprogramming)を用いて希突起膠前駆細胞を誘導するための組成物。
- カルシウムチャネル作動剤(Calcium channel agonist)をさらに含有することを特徴とする、請求項11に記載の組成物。
- RG108、BIX01294、SP600125、リゾホスファチジン酸(Lysophosphatidic acid)、Bayk8644、ホルスコリン(Forskolin)、デキサメタソン(Dexamethasone)、EX527およびロリプラム(Rolipram)よりなる群から選択されたいずれか一つをさらに含有することを特徴とする、請求項11に記載の組成物。
- カルシウムチャネル作動剤は、ホルスコリン(Forskolin)であることを特徴とする、請求項12に記載の組成物。
- 希突起膠前駆細胞は、Sox1、Sox2およびPax6マーカーを発現しないことを特徴とする、請求項11に記載の組成物。
- 請求項1に記載の方法で調製された希突起膠前駆細胞をチアゾビビン(Thiazovivin)、ホルスコリン(Forskolin)およびLIF(Leukemia Inhibitory Factor)並びにT3(triiodo−L−thyronine)が含まれた培地で培養する段階を含む、希突起膠前駆細胞を希突起膠細胞に分化させる方法。
- 前記培地は、N2、B27、ペニシリン/ストレプトマイシン、非必須アミノ酸、およびアスコルビン酸が含まれたDMEMであることを特徴とする、請求項16に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150069696 | 2015-05-19 | ||
KR10-2015-0069696 | 2015-05-19 | ||
KR1020160043593A KR101782488B1 (ko) | 2015-05-19 | 2016-04-08 | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 |
KR10-2016-0043593 | 2016-04-08 | ||
PCT/KR2016/004603 WO2016186346A1 (ko) | 2015-05-19 | 2016-05-02 | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018516570A JP2018516570A (ja) | 2018-06-28 |
JP6522790B2 true JP6522790B2 (ja) | 2019-05-29 |
Family
ID=57706520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017560793A Active JP6522790B2 (ja) | 2015-05-19 | 2016-05-02 | Oct4が導入されたヒト体細胞からダイレクトリプログラミングを用いた希突起膠前駆細胞を誘導する方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20180155685A1 (ja) |
EP (1) | EP3321354A4 (ja) |
JP (1) | JP6522790B2 (ja) |
KR (1) | KR101782488B1 (ja) |
CN (1) | CN107810268B (ja) |
AU (1) | AU2016264166B2 (ja) |
CA (1) | CA2986368C (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101782488B1 (ko) | 2015-05-19 | 2017-09-28 | 주식회사 스템랩 | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 |
CN107099499B (zh) * | 2016-06-03 | 2021-02-02 | 中国人民解放军军事医学科学院野战输血研究所 | 将消化道来源上皮细胞重编程为内胚层干/祖细胞的小分子化合物组合、重编程试剂盒 |
WO2019059713A2 (ko) * | 2017-09-21 | 2019-03-28 | 한국생명공학연구원 | 자연살해세포의 제조방법 및 그의 용도 |
WO2019241620A1 (en) * | 2018-06-14 | 2019-12-19 | Academia Sinica | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells |
CN110714024A (zh) * | 2018-07-13 | 2020-01-21 | 中国科学院上海生命科学研究院 | 建立自外周血单核细胞的神经前体细胞及其构建方法 |
CA3155277A1 (en) * | 2019-09-20 | 2021-03-25 | Korea Research Institute Of Bioscience And Biotechnology | Production method for induced dopaminergic neuronal progenitors, using direct reprogramming |
CN116529361B (zh) * | 2019-10-18 | 2024-01-26 | 北赛泓升(北京)生物科技有限公司 | 使用多顺反子sox2、klf4和任选的c-myc产生诱导多能干细胞 |
CN117025503A (zh) * | 2022-05-10 | 2023-11-10 | 上海赛立维生物科技有限公司 | 肝内胆管前体样细胞、细胞制剂及制备方法和应用 |
WO2024012502A1 (zh) * | 2022-07-12 | 2024-01-18 | 南京瑞初医药有限公司 | 组合物及其使用方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100357402B1 (ko) * | 1998-07-08 | 2003-03-03 | 애경산업(주) | 죽내피 추출물을 함유한 미백화장료 |
WO2011006205A1 (en) | 2009-07-15 | 2011-01-20 | Regenertech Pty Limited | Method of producing progenitor cells from differentiated cells |
JP2012031127A (ja) * | 2010-08-03 | 2012-02-16 | Nagoya Univ | 臍帯由来間葉系幹細胞を含む組成物 |
KR101357402B1 (ko) | 2012-01-20 | 2014-02-07 | 주식회사 스템랩 | 유전자 도입 없이 직접적 역분화를 통해 체세포로부터 신경상피세포 및 신경줄기세포를 유도하는 방법 |
CN102604894B (zh) * | 2012-02-29 | 2014-07-30 | 中国科学院广州生物医药与健康研究院 | 用于制备神经干细胞的培养基及其用途 |
KR101816103B1 (ko) | 2015-04-13 | 2018-01-08 | 고려대학교 산학협력단 | 소분자 화합물을 이용한 인간 섬유아세포를 신경줄기세포로 직접 전환하는 방법 |
WO2016167528A1 (ko) * | 2015-04-13 | 2016-10-20 | 고려대학교산학협력단 | 소분자 화합물을 이용한 인간 섬유아세포를 신경줄기세포로 직접 전환하는 방법 |
KR101782488B1 (ko) | 2015-05-19 | 2017-09-28 | 주식회사 스템랩 | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 |
-
2016
- 2016-04-08 KR KR1020160043593A patent/KR101782488B1/ko active IP Right Grant
- 2016-05-02 US US15/575,369 patent/US20180155685A1/en not_active Abandoned
- 2016-05-02 CA CA2986368A patent/CA2986368C/en active Active
- 2016-05-02 EP EP16796673.8A patent/EP3321354A4/en active Pending
- 2016-05-02 AU AU2016264166A patent/AU2016264166B2/en active Active
- 2016-05-02 CN CN201680038355.7A patent/CN107810268B/zh active Active
- 2016-05-02 JP JP2017560793A patent/JP6522790B2/ja active Active
-
2019
- 2019-06-03 US US16/429,062 patent/US10767163B2/en active Active
-
2020
- 2020-08-13 US US16/992,136 patent/US11572540B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3321354A4 (en) | 2018-11-14 |
CN107810268B (zh) | 2021-09-24 |
AU2016264166A1 (en) | 2017-12-07 |
CN107810268A (zh) | 2018-03-16 |
KR101782488B1 (ko) | 2017-09-28 |
EP3321354A1 (en) | 2018-05-16 |
US20180155685A1 (en) | 2018-06-07 |
CA2986368A1 (en) | 2016-11-24 |
US20190284528A1 (en) | 2019-09-19 |
AU2016264166B2 (en) | 2019-09-19 |
CA2986368C (en) | 2021-06-01 |
JP2018516570A (ja) | 2018-06-28 |
KR20160136224A (ko) | 2016-11-29 |
US11572540B2 (en) | 2023-02-07 |
US20210017491A1 (en) | 2021-01-21 |
US10767163B2 (en) | 2020-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6522790B2 (ja) | Oct4が導入されたヒト体細胞からダイレクトリプログラミングを用いた希突起膠前駆細胞を誘導する方法 | |
JP7407865B2 (ja) | 細胞の再プログラミングのための方法とその用途 | |
Liu et al. | Neural crest stem cells and their potential therapeutic applications | |
US11512285B2 (en) | Method of preparing induced neural stem cells reprogrammed from non-neuronal cells using HMGA2 | |
JP7094567B2 (ja) | 神経堤細胞および交感神経細胞の製造方法 | |
KR100794359B1 (ko) | Shh를 이용한 아스트로사이트의 신경줄기세포로의역분화 | |
KR101211624B1 (ko) | Shh, FGFR 티로신 키나아제 억제제, MEK 억제제와 GSK 억제제를 이용하여 체세포로부터 배아줄기세포 유사세포로의 역분화를 유도하는 조성물 및 이를 이용한 배아줄기세포 유사세포의 제조방법 | |
WO2016186346A1 (ko) | Oct4가 도입된 인간체세포로부터 직접적 리프로그래밍을 통한 희소돌기아교 전구세포를 유도하는 방법 | |
Raciti | Reprogramming fibroblasts to Neural-Stem-like cells by structured overexpression of pallial patterning genes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190325 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190424 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6522790 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |